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Background: Bone morphogenetic protein-7 (BMP7) can prevent/reverse fibrosis, but mechanisms are unclear.
Results: BMP7 prevents/reverses myofibroblast formation through cell-surface hyaluronan internalization into catalytic endo-
somes. Hyaluronidase-2 and variant CD44v7/8 mediate this process.
Conclusion: Alterations in hyaluronan are critical in prevention/reversal of myofibroblast differentiation.
Significance:Anovelmechanismof BMP7 action is described and identifies CD44v7/8 and hyaluronidase-2 as potential targets
in preventing fibrotic pathology.
Hyaluronan (HA) promotes transforming growth factor
(TGF)-1-driven myofibroblast phenotype. However, HA can
also have disease-limiting activity. Bone morphogenetic pro-
tein-7 (BMP7) is an antifibrotic cytokine that antagonizes TGF-
1, and isolated studies have demonstrated that HA can both
mediate andmodulate BMP7 responses. In this study, we inves-
tigated whether BMP7 canmodulate HA in a manner that leads
to prevention/reversal of TGF-1-driven myofibroblast differ-
entiation in human lung fibroblasts. Results demonstrated that
BMP7 prevented and reversed TGF-1-driven myofibroblast
differentiation through a novel mechanism. BMP7 promoted
the dissolution and internalization of cell-surface HA into cyto-
plasmic endosomes. Endosomal HA co-localized with the HA-
degrading enzymes, hyaluronidase-1 and hyaluronidase-2
(Hyal2). Moreover, BMP7 showed differential regulation of
CD44 standard and variant isoform expression, when compared
with TGF-1. In particular, BMP7 increasedmembrane expres-
sion of CD44v7/8. Inhibiting CD44v7/8 as well as blocking
Hyal2 and the Na/H exchanger-1 at the cell-surface pre-
vented BMP7-driven HA internalization and BMP7-mediated
prevention/reversal of myofibroblast phenotype. In summary, a
novelmechanismofTGF-1 antagonismbyBMP7 is shown and
identifies alteration in HA as critical in mediating BMP7
responses. In addition, we identify Hyal2 and CD44v7/8 as new
potential targets for manipulation in prevention and reversal of
fibrotic pathology.
Bone morphogenetic protein-7 (BMP7) is a member of the
transforming growth factor- (TGF-) superfamily that dem-
onstrates reduced expression in progressive renal diseases.
Studies in animal models of renal disease, including ischemic
reperfusion injury, unilateral urethral obstruction, nephro-
toxin-induced glomerulonephritis, and streptozotocin-in-
duced diabetic nephropathy, have shown that BMP7 can both
prevent and reverse renal fibrosis (1–4). Studies in animalmod-
els of pulmonary and liver fibrosis have demonstrated similar
benefits (5–7).However, BMP7has also been implicated in pro-
gression of bone metastasis in osteotropic cancers and in pro-
moting ectopic bone formation, and thus it is not currently
viable as a clinical therapy (8). Dissecting the mechanisms by
which BMP7 prevents and reverses fibrosis may provide more
suitable therapeutic targets. There are data indicating that the
actions of BMP7 are, in part, related to antagonism of the bio-
logical effects of TGF-1, a pro-fibrotic mediator (9–11).
BMP7 has been shown to attenuate TGF-1-dependent Smad3
signaling (10). However, other studies have shown that Smad-
independent, MAPK-signaling events are central to TGF-1-
driven renal fibrosis (11, 12). Hence, the anti-fibrotic mecha-
nisms of BMP7 are not yet fully elucidated.
Hyaluronan (HA)2 is a connective tissue glycosaminoglycan,
which in vivo is present as a highmolecular mass component of
extracellular matrices. It is synthesized by three mammalian
HA synthase isoenzymes (HAS1, HAS2, and HAS3), and its
breakdown is mediated by the hyaluronidase (Hyal) group of
enzymes. HA regulates cellular processes through interaction
with cell-surface receptors (principally CD44) and has been
implicated in numerous biological processes, including embry-
onic development, wound healing, chronic inflammation, and
tumor progression (13–16). Therefore, HA has an important
role in maintaining tissue homeostasis.
Alterations in HA generation and turnover have also been
associated with promotion of disease states. Increased expres-
sion of HA has been demonstrated in numerous fibrotic condi-
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tions associated with organ dysfunction, including IgA
nephropathy, diabetic nephropathy, pulmonary fibrosis, and
cirrhotic liver disease (17–24). We have previously shown that
changes in HA synthesis and macromolecular organization are
key in directing TGF-1-driven differentiation of fibroblasts to
myofibroblasts, the principal effector cells in fibrosis (12,
25–27). TGF-1 stimulation directs HAS2-driven assembly of
HA into pericellular coats, which promotesmembrane redistri-
bution of CD44. This results in its physical co-localization with
the epidermal growth factor receptor (EGFR) and subsequent
selective activation of the MAPK/ERK signaling pathway nec-
essary for myofibroblast formation (12, 27). Numerous reports
have indicated that HA assembly and its conformation within
the pericellularmatrix are crucial in determining its subsequent
biological actions. For example, interleukin-1 (IL-1)-medi-
ated formation of HA pericellular protrusions promotes fibro-
blast immune activation through fibroblast-monocyte interac-
tions, whereas pericellular HA cable-like structures are shown
to be anti-inflammatory and prevent monocyte-dependent
inflammatory cytokine production (28, 29). Thus, it is clear that
under specific biological contexts HA may also have the ability
to function in the prevention of disease.
There is some evidence that HA can both mediate and mod-
ulate BMP7 responses. In chondrocytes, BMP7-dependent
Smad1 signaling was mediated through CD44-Smad1 interac-
tions (30). Other studies demonstrated that pericellular HA
augments BMP7 Smad signaling (31). In renal epithelial cells,
BMP7 has also been shown to induce the formation of HA
cables (32). However, whether HA plays a specific role in
BMP7-mediated antagonism of TGF-1 actions is not known.
In this work, we demonstrate a novel mechanism in which BMP7
reverses TGF-1 induction of myofibroblast differentiation in
human lung fibroblast cultures by internalizing pericellular HA
into catalytic endosomes within the cytoplasm and preventing
TGF-1-driven pericellular HA accumulation. The CD44 variant
isoform,CD44v7/8, andmembrane-boundHyal2 are both critical
for this process of HA internalization and thus potentially present
new targets for study and intervention in fibrosis.
EXPERIMENTAL PROCEDURES
Materials—All reagents were purchased from Sigma (Poole,
UK) or Life Technologies and Invitrogen (Paisley, UK) unless oth-
erwise stated. Reverse transcription reagents, siRNA transfection
reagents, andquantitativePCR(QPCR)primersandreagentswere
purchased from Invitrogen and Applied Biosystems (Cheshire,
UK). Other reagents used were recombinant human BMP7
(Merck Millipore, Darmstadt, Germany), recombinant human
TGF-1 (R&D Systems, Abingdon, UK), and the selective NHE1
inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA; Sigma).
Cell Culture—Human lung fibroblasts (AG02262) were pur-
chased from Coriell Cell Repositories (Coriell Institute for
Medical Research, Camden, NJ). The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) and F12 con-
taining 5 mM glucose, 2 mmol/liter L-glutamine, 100 units/ml
penicillin, 100 g/ml streptomycin, and supplemented with
10% fetal bovine serum (Biological Industries Ltd., Cumber-
nauld, UK). The cells were maintained at 37 °C in a humidified
incubator in an atmosphere of 5% CO2, and fresh growth
medium was added to the cells every 3 to 4 days until the cells
were ready for experimentation. The cells were incubated in
serum-free medium for 48 h before use in all experiments, and
all experiments were performed under serum-free conditions
unless otherwise stated. All experiments were undertaken
using cells at passage 6–10.
Cellular Treatments—Phenotypic differentiation of fibro-
blasts was induced by stimulation with 10 ng/ml TGF-1 for
72 h according to time course and dose-response experiments
and according to our previous protocols (33). Time course and
dose-response experiments were also initially done to deter-
mine the optimum concentration and incubation times with
BMP7. A dose of 400 ng/ml BMP7 was subsequently used in all
experiments.
Two experimental cell systems were utilized to determine
effects of BMP7 and related alterations in HA on TGF-1
responsiveness, a prevention model and a reversal model of
fibrosis. For the prevention model, cells were either treated
with TGF-1 and BMP7 at the same time (prevention I) or cells
were pretreated with BMP7 prior to stimulation with TGF-1
(prevention II). For the reversal model, cells were first stimu-
lated with TGF-1 to induce differentiation and then subse-
quently treated with BMP7. These treatment conditions and
incubation times are more clearly demonstrated in Table 1.
HA ELISA—An ELISA-like assay (HA ELISA) was commer-
cially purchased (Corgenix, Broomfield, CO) and used to assess
the concentrations of intracellular HA, HA in conditioned cell
culture medium, and on the cell surface. Briefly, conditioned
cell culture medium was removed and transferred into Eppen-
dorf microcentrifuge tubes (soluble HA) and kept on ice. Cells
were then incubated with trypsin/EDTA for 5 min at room
temperature, transferred into microcentrifuge tubes, and cen-
trifuged at 4000  g for 5 min at 4 °C. The supernatant was
transferred to Eppendorf microcentrifuge tubes, and trypsin
was deactivated by heating to 90 °C for 5 min (cell-surface HA)
and then kept on ice. The cell pellet was resuspended in dilute
(10% v/v) RIPA buffer and kept on ice for 10 min. The solution
was centrifuged again, and the supernatant transferred to fresh
microcentrifuge tubes (intracellular HA). Samples were then
analyzed by Corgenix HA ELISA kits (Corgenix), according to
the manufacturer’s protocol.
Reverse Transcription and Real Time Quantitative PCR (RT
and RT-QPCR)—RT-QPCR was used to assess -SMA
(ACTA2),CD44, Hyal1, Hyal2, HAS1, HAS2, andHAS3mRNA
expressions. Primers and probes for these genes were commer-
cially designed and purchased from Applied Biosystems. The
cells were grown in 35-mm dishes and washed with PBS before
lysis with TRI Reagent and RNA purification according to the
TABLE 1
Experimental cell treatment systems
Treatment
conditions 0–72 h 72–144 h
Untreated control
TGF-1 10 ng/ml TGF-1 10 ng/ml TGF-1
BMP7 400 ng/ml BMP7 400 ng/ml BMP7
Prevention I 10 ng/ml TGF-1
and 400 ng/ml BMP7
10 ng/ml TGF-1
and 400 ng/ml BMP7
Prevention II 400 ng/ml BMP7 10 ng/ml TGF-1
Reversal 10 ng/ml TGF-1 400 ng/ml BMP7
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manufacturer’s protocol. Reverse transcription was done using
the high capacity cDNA reverse transcription kit according
to the manufacturer’s protocol (Applied Biosystems). This kit
uses the random primer method for initiating cDNA synthesis.
As a negative control, reverse transcription was done with ster-
ile H2O replacing the RNA sample. QPCR was done using the
ViiA7 real time QPCR system from Applied Biosystems in a
final volume of 20 l per sample as follows: 1 l of reverse
transcription product, 1l of target gene primers and probe, 10
l of TaqManFastUniversal PCRMasterMix, and 8l of sterile
RNase-freewater. Amplificationwas done using a cycle of 95 °C
for 1 s and 60 °C for 20 s for 40 cycles.QPCRwas simultaneously
performed for ribosomal RNA (primers and probe commer-
cially designed and purchased from Applied Biosystems) as a
standard reference gene.
For assessment of CD44 variant isoform expression, custom
primer pairs were designed and purchased from Invitrogen.
Primer pairs used are shown in Table 2.
QPCR for custom primer pairs was done with the ViiA7 real
time QPCR system from Applied Biosystems in a final volume
of 20 l per sample as follows: 1 l of reverse transcription
product; 0.6 l of 10 M target gene forward primer and 0.6 l
of 10M target gene reverse primer; 10l of Power SYBRGreen
Mastermix; and 7.8 l of sterile RNase-free water. Amplifica-
tion used a cycle of 95 °C for 15 s and 60 °C for 1 min for 40
cycles, followed by amelt-curve stage at 95 °C for 15 s, 60 °C for
1 min, and a final step of 95 °C for 15 s. QPCR was simultane-
ously performed forGAPDHmRNA expression (custom prim-
ers designed andpurchased fromAppliedBiosystems) as a stan-
dard reference gene. As a negative control, PCRwas performed
with sterile H2O replacing the cDNA sample.
The comparative CT method was used for relative quantifi-
cation of gene expression. The CT (threshold cycle where
amplification is in the linear range of the amplification curve)
for the standard reference gene (rRNA/GAPDH) was sub-
tracted from the target gene CT to obtain the CT. The mean
CT values for replicate samples were then calculated. The
expression of the target gene in experimental samples relative
to expression in control samples was then calculated using
the following equation: 2(CT(1)  CT(2)), whereCT(1) is the
mean CT calculated for the experimental samples, and
CT(2) is the mean CT calculated for the control samples.
siRNA Transfection—Transient transfection of fibroblasts
was donewith specific siRNAnucleotides (AppliedBiosystems)
targeting Hyal1, Hyal2, or CD44v7/8. Transfection was done
using Lipofectamine 2000 transfection reagent (Invitrogen) in
accordancewith themanufacturer’s protocol. Briefly, cellswere
grown to 70% confluence in antibiotic-free medium in either
35-mm dishes or 8-well Permanox chamber slides. Transfec-
tion reagent (2% v/v) was diluted inOpti-MEMreduced growth
medium (GIBCO) and left to incubate for 5 min at room tem-
perature. The specific siRNA oligonucleotides were diluted in
Opti-MEM reduced growth medium to achieve a final concen-
tration of 30 nM. The transfection agent and siRNA mixtures
were then combined and incubated at room temperature for an
additional 20 min. The newly formed transfection complexes
were subsequently added to the cells and incubated at 37 °C
with 5%CO2 for 24 h in serum-freemedium before experimen-
tation. As a control, cells were transfectedwith negative control
siRNA (a scrambled sequence that bears no homology to the
human genome) (Applied Biosystems).
Immunocytochemistry—Cells were grown to 70% confluence
in 8-well Permanox chamber slides. The culture medium was
removed, and the cells washed with sterile PBS before fixation
in 4% paraformaldehyde for 10min at room temperature. After
fixation, cells were permeabilized with 0.1% (v/v) Triton X-100
in PBS for 10 min at room temperature. Slides were blocked
with 1% bovine serum albumin (BSA) for 1 h before a further
washing step with 0.1% (w/v) BSA in PBS. Subsequently, the
slides were incubatedwith the primary antibody diluted in 0.1%
BSA and PBS for 2 h at room temperature. When visualizing
HA, biotinylated HA-binding protein (bHABP) was used in
place of primary antibody. After a further washing step, slides
were incubated with AlexaFluor 488-conjugated and/or Alexa-
Fluor 555-conjugated secondary antibodies for 1 h at room
temperature. Avidin-FITC was used in place of a secondary
antibody when visualizing HA. Cell nuclei were stained with
Hoechst solution. Cells were then mounted and analyzed by
confocal and fluorescent microscopy. A co-localization scatter
plot was used to quantify the level of co-localization present
between distinct antibody stains in selected experiments.
The following primary antibodies were used: mouse anti-
human-SMA (Sigma); rat anti-humanCD44 antibody (Merck
Millipore; A020); mouse anti-human EGFR antibody (Merck
Millipore); biotinylated bHABP (Seikagaku Corp., Tokyo,
Japan); mouse anti-human EEA1 antibody (Santa Cruz Bio-
technology Inc., Heidelberg, Germany); mouse anti-human
Cav1 antibody (Sigma); rabbit anti-human Hyal1 antibody and
rabbit anti-human Hyal2 antibody (gift from Dr. Robert Stern,
Department of Pathology, University of California, San Fran-
cisco); mouse anti-human CD44v7/8 antibody (Thermo Fisher
Scientific, Leicestershire, UK); and cholera toxin subunit B
Alexa Fluor 594 conjugate (Molecular Probes, Invitrogen). The
following secondary antibodies were used: rabbit anti-rat Alexa-
Fluor 555, goat anti-mouse AlexaFluor 488, goat anti-rabbit
AlexaFluor 488, goat anti-rabbit AlexaFluor 555 (Merck Milli-
pore); and avidin-FITC (Vector Laboratories, Burlingame, CA).
CD44 Variant Isoform Identification and Polymerase Chain
Reaction (PCR)—Specific primer pairs were designed and pur-
chased (Invitrogen) to targetCD44v7 andCD44v8. Two primer
sets were used for CD44v7 analysis as follows: set one forward
5-TCAATGCTTCAGCTCCACCT-3 and reverse 5-TCTC-
CCATCCTTCTTCCTGCTT-3; set two forward 5-GAATC-
CCTGCTACCACAGCCTC-3 and reverse 5-CAAAGCCA-
AGGCCAAGAGGGATGC-3. The following two primer sets
TABLE 2
Forward and reverse primer pairs for CD44 standard and variant
isoforms
CD44s Forward 5-GCTACCAGAGACCAAGACACA-3
Reverse 5-GCTCCACCTTCTTGACTCC-3
CD44v7 Forward 5-GAATCCCTGCTACCACAGCCTC-3
Reverse 5-TCTCCCATCCTTCTTCCTGCTT-3
CD44v8 Forward 5-ATGTGTCTTGGTCTCGCGTT-3
Reverse 5TCCCTGCTACCAATATGGACTC-3
CD44v3/7 Forward 5-TTATCTCCAGCACCACAGCCTC-3
Reverse 5-TCTTGGTCTCCCATCCTTCTTC-3
CD44v7/8 Forward 5AGGAAGAAGGATGGATATGGACT-3
Reverse 5-GTCTTGGTCTCGCGTTGTCA-3
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were used for CD44v8 analysis as follows: set one forward
5-TCAATGCTTCAGCTCCACCT-3 and reverse 5-TCCC-
TGCTACCATATGGACTC-3; set two forward 5-ATGTGT-
CTTGGTCTCGCGTT-3 and reverse 5-CAAAGCCA-
AGGCCAAGAGGGATGC-3.
Fragments were amplified using the Phusion High Fidelity
DNA polymerase system (New England Biolabs, Inc.). Briefly, 4
l of 5 High Fidelity buffer, 0.4 l of dNTPs, 1 l of 10 M
forward primer, 1 l of 10 M reverse primer, 0.2 l of Phusion
DNA polymerase, 10 ng of cDNA template, and distilled H2O
were added to a final volume of 20l. Samples were PCR ampli-
fied with thermocycling conditions of: 98 °C for 30 s, 35 cycles
of 98 °C for 10 s, 65 °C for 30 s, and 72 °C for 30 s. This was
followed by a final extension at 72 °C for 10 min. The resultant
PCR products were run on 1% agarose gels by flatbed electro-
phoresis. Bands were pictured and then excised for gel extrac-
tion and subsequent DNA sequencing (Eurofins MWG
Operon, Ebersberg, Germany) to identify key CD44 variant
isoforms amplified with BMP7 treatment.
Statistical Analysis—Two-tailed, unpaired Student’s t tests
were done to assess statistical differences between the two
experimental groups. For experiments with multiple experi-
mental conditions, one-way analysis of variance was used to
identify statistical differences across groups, followed by post-
test Bartlett’s and two-tailed unpaired Student’s t tests. Pear-
son’s correlation was used to determine statistical significance
of co-localization scatter plots. Graphical data are expressed as
means  S.E. All data were analyzed using GraphPad Prism
version 4.01. *, p  0.05, and **, p  0.01, were considered
statistically significant.
RESULTS
BMP7 Both Prevents and Reverses Differentiation of Fibro-
blasts to Myofibroblasts—Exposure of human lung fibroblasts
to different concentrations of TGF-1 demonstrated that the
minimum dose of TGF-1 required to promote myofibroblast
differentiation was 10 ng/ml. This was assessed by positive
staining for themyofibroblast marker, -SMA (Fig. 1A). Subse-
quent incubations of fibroblasts with 10 ng/ml TGF-1 for dif-
ferent times demonstrated that 72-h incubations with this dose
of TGF-1 was required to promote complete myofibroblast
differentiation (Fig. 1B). Subsequently, myofibroblast cultures
were assessed to confirm stable differentiation of cells. Fibro-
blasts were initially stimulated with 10 ng/ml TGF-1 to pro-
mote myofibroblast differentiation. Following this, TGF-1
was removed from the cultures, and incubations were contin-
ued for a further 72 h. -SMA staining persisted in the myofi-
broblast cultures following the removal of TGF-1, indicating
that these were stably differentiated cells, and their myofibro-
blast phenotype was not reversed by TGF-1 removal (Fig. 1C).
Fibroblast and myofibroblast cultures were treated with dif-
ferent doses of BMP7 for various times to determine the effect
on TGF-1-driven myofibroblast differentiation. Initially,
fibroblasts were pretreatedwith varying doses of BMP7 prior to
72 h of TGF-1 exposure. These experiments demonstrated
maximal prevention of TGF-1-dependent myofibroblast differ-
entiation by BMP7 at a dose of 400 ng/ml (Fig. 1D). Similarly, 400
ng/ml BMP7 was the maximal dose required to reverse TGF-1-
driven myofibroblast differentiation (Fig. 1E). Moreover, experi-
ments were performed to determine the necessary BMP7 incuba-
tion times for maximal prevention/reversal of myofibroblast
phenotype. Results demonstrated significant attenuation of -
SMA mRNA following 24 h of 400 ng/ml BMP7 exposure, with
maximal attenuation demonstrated at 72 h (Fig. 1F).
All experiments were consequently performed at 72 h with
10 ng/ml TGF-1 and at 72 h with 400 ng/ml BMP7. Confir-
mation experiments were repeated using these parameters.
Stimulation of fibroblasts with 10 ng/ml TGF-1 led to positive
immunocytochemical staining for -SMA. Unstimulated cells
(control) and cells treated with BMP7 alone had minimal
-SMA staining as expected. Fibroblasts that were treated with
BMP7 and TGF-1 concurrently (prevention I) or fibroblasts
that were first pretreated with BMP7 prior to incubation with
TGF-1 (prevention II) demonstrated minimal positive -
SMA staining. Similarly, fibroblasts that were first treated with
TGF-1 to induce myofibroblast differentiation and subse-
quently treated with BMP7 showed negligible staining for
-SMA (reversal) (Fig. 2A).
These results were further confirmed by assessing cytoskel-
etal reorganization in fibroblasts in response to BMP7. Cells
were stained with FITC-phalloidin, a fluorescent probe that
binds filamentous actin. Undifferentiated fibroblasts displayed
a narrow spindle-shaped appearancewith actin fibers forming a
complex meshwork at the periphery of cells. No obvious bun-
dles of actin fibers were evident. These are the results depicted
in unstimulated cells and cells treated with BMP7 alone. Stim-
ulation with TGF-1 leading to myofibroblast differentiation
led to prominent cytoskeletal reorganization with the actin fil-
aments coalescing to form thick bundles that extend from end
to end of the cells. However, pretreatment and co-treatment
with BMP7 (prevention I and II), as well as treatment with
BMP7 following TGF-1 (reversal), prevented and reversed
TGF-1-driven reorganization of the filamentous actin cyto-
skeleton (Fig. 2A). Assessment of -SMA expression in fibro-
blasts using quantitative PCR substantiated these results,
demonstrating thatBMP7canbothprevent and reverseTGF-1-
induced up-regulation in -SMAmRNA expression (Fig. 2B).
BMP7Drives Internalization of HA into Intracellular Vesicles
in Fibroblasts andMyofibroblasts—Previous studies have dem-
onstrated an increase in extracellular and pericellular HA in
response to TGF-1 (33, 34). An ELISA-like assay was used to
assess HA levels in the different BMP7 experimental models.
The results demonstrated that TGF-1 significantly increased
HA levels above control in the extracellular and pericellular
areas, although BMP7 did not (Fig. 3, A and B). In contrast,
BMP7 treatments significantly increased levels of intracellular
HA, although TGF-1 did not (Fig. 3C).
HA localization and distribution in fibroblasts were assessed
using immunocytochemical staining for FITC-labeled HABP.
In unstimulated fibroblasts, intracellular HA was apparent and
appeared to be distributed diffusely within the cytoplasm. In
TGF-1-induced myofibroblasts, HA was mainly localized at
the cell surface. These findings are in keepingwith our previous
studies (12, 28). Fibroblasts treated with BMP7 demonstrated
predominantly intracellular HA staining. However, the HA in
these cells appeared to be localized in distinct punctate areas
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within the cytoplasm, in a pattern suggesting localization
within vesicles. This pattern of HA staining was also demon-
strated in fibroblasts pretreated and co-treated with BMP7 and
TGF-1 (Fig. 4A). To confirm that these areas of HA staining
were localized within the cytoplasm rather than at the cell sur-
face, fibroblasts were treated with Streptomyces hyaluronidase
to remove any cell-surface HA prior to HA staining techniques.
These experiments confirmed the intracellular localization of
HA in response to BMP7 (Fig. 4B).
BMP7 Is Associated with Alterations in mRNA Expression of
Hyaluronan Synthase 2 (HAS2), CD44, and Hyaluronidase 1
and 2—Previous research in this area has demonstrated that
TGF-1 mediated fibroblast to myofibroblast differentiation,
and generation of the pericellular HA coat is predominantly
dependent on HA synthase isoforms HAS1 and HAS2 (26, 35).
In these experiments TGF-1 significantly increasedHAS1 and
HAS2mRNA expression in the human lung fibroblasts (Fig. 5,
A and B). In comparison, prevention and reversal of myofibro-
blast phenotype associated with BMP7 stimulation were asso-
ciated with induction in gene expression of all three HA syn-
thase isoforms (HAS1, HAS2, and HAS3) with a significant
increase in HAS2 over that induced by TGF-1 (Fig. 5, A–C).
Furthermore, although TGF-1-driven fibroblast differentia-
tionwas associatedwith decreasedCD44 andHyal1 expression,
BMP7 stimulation increased expression of both of these pro-
teins (Fig. 5, D and E). Hyal2 mRNA was increased, compared
with controls, similarly by both TGF-1 and BMP7 (Fig. 5F).
BMP7 Induces HA Internalization into Intracellular Cata-
lytic Endosomes Containing Hyal1 and Hyal2—Co-staining of
HA (HABP) with Cav1 (caveolin marker), EEA1 (endosomal
FIGURE1.10ng/ml72-hTGF-1 induces stablemyofibroblastdifferentiation, andprevention/reversal ofmyofibroblastphenotype is inducedby400
ng/ml72-hBMP7.A–C, fibroblastsweregrown to70%confluencebeforeundergoinggrowth arrest in serum-freemedium for 48h.A,mediumwas replaced
with serum-free medium containing 0, 5, 10, 20, 30, and 50 ng/ml TGF-1 and the incubations continued for 72 h. B, medium was replaced with serum-free
medium containing 10 ng/ml TGF-1 for 0, 8, 12, 24, 48, and 72 h. C,mediumwas then replacedwith serum-freemedium containing 10 ng/ml TGF-1 for 72 h
and then subsequently again replaced with serum-freemedium, and the incubations continued for a further 0, 24, 48, and 72 h. The cells were then fixed and
stained for -SMA and viewed under UV light. D–F, fibroblasts were grown to70% confluence before undergoing growth arrest in serum-free medium for
48 h. D, cells were treated with 0, 50, 100, 200, 400, and 800 ng/ml BMP7 and the incubations continued for 72 h; thenmediumwas replaced with serum-free
medium containing 10 ng/ml TGF-1 for 72 h. E, cells were treated with 10 ng/ml TGF-1 for 72 h before undergoing treatment with 0, 50, 100, 200, 400, and
800 ng/ml BMP7 for a further 72 h. F, cells were treatedwith 400 ng/ml BMP7 for 0, 8, 12, 24, 48, and 72 h; thenmediumwas replacedwith serum-freemedium
containing 10 ng/ml TGF-1 for a further 72 h. RNA extraction and RT-QPCR assessment for -SMA mRNA expression was subsequently performed. Control
experiments included cells treated with serum-free medium alone, cells treated with 10 ng/ml TGF-1 alone, and cells treated with 400 ng/ml BMP7 alone.
White scale bars represent 20 micrometers.
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marker), or LAMP1 (lysosomal marker) was used to assess the
internalization of HA into caveolar, endosomal, or lysosomal
vesicles, respectively. The presence of high cholesterol lipid
rafts within the vesicular membrane was also investigated by
co-staining for HA and the lipid raft marker (cholera toxin sub-
unit B). Intracellular HA within the vesicles in BMP7-treated
FIGURE 2. BMP7 prevents and reverses myofibroblast phenotype. A, fibroblasts were grown to 70% confluence before undergoing growth arrest in
serum-free medium for 48 h. Cells were then treated under the various cytokines according to the experimental models described under “Experimental
Procedures.” Subsequently, cells were fixed and stained for -SMA (top row) and F-actin (bottom row). Images shown are representative of three individual
experiments. B, fibroblasts were grown to confluence before growth arrest in serum-free medium for 48 h. Cells were then treated under the various
experimental models as described above before extraction with TRIzol reagent. RNAs were purified, reverse-transcribed, and assessed for -SMA mRNA
expression using RT-QPCR. Results are shown as the mean S.E. of three individual experiments. Statistical analysis used the paired Student’s t test with p
0.05 considered as statistically significant.
FIGURE 3.BMP7 treatment alters cellular HAdistribution resulting in internalization of HA inmyofibroblasts.Cells were grown to confluence in 35-mm
dishes; growth-arrested for 48 h, and incubated with the indicated cytokine treatments in the experimental models as described under “Experimental
Procedures.” HA ELISA was used to analyze the concentrations of HA in conditioned cell culturemedia (A), cell-surface trypsinates (B), and intracellular lysates
(C). Results are expressed as the mean S.E. of three individual experiments. Statistical analysis used the paired Student’s t test with p 0.05 considered as
statistically significant. N/S, not significant.
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FIGURE 4. BMP7 treatment internalizes HA into intracellular vesicles. Cells were grown to 70% confluence before undergoing growth arrest in serum-free
mediumfor 48h. Cellswere then treatedunder various cytokine conditions, according to theexperimentalmodelsdescribedunder “Experimental Procedures”
and subsequently fixed, permeabilized, and stained for HA using bHABP and avidin-FITC. A, HA visualization using laser scanning confocal microscopy
following various cytokine treatment conditions. B, cells treated with hyaluronidase prior to fixation. All images are representative of three individual experi-
ments. Original magnification is shown on individual panels.
FIGURE 5. BMP7 alters HA-associated gene expression. Fibroblasts were grown to confluence before undergoing growth arrest in serum-free medium for
48 h. Cells were then treated under various cytokine conditions according to the experimental models described under “Experimental Procedures” before
extraction with TRIzol reagent. RNAs were purified, reverse-transcribed and assessed for: HAS1 (A), HAS2 (B), HAS3 (C), CD44 (D), Hyal1 (E), and Hyal2 (F) mRNA
expression using RT-QPCR. Results are shown as the mean S.E. of three individual experiments. Statistical analysis used the paired Student’s t test with p
0.05 considered as statistically significant, and comparison is made between control and all other treatment conditions.
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cells co-localized positively with the endosomal marker EEA1
(Fig. 6A) but not with LAMP1 (Fig. 6B). The level of association
was confirmed by co-localization of scatter plots, which dem-
onstrated significant areas of HA with EEA1 (Pearson’s corre-
lation coefficient mean r	 0.83 0.072 (HA/EEA1) and mean
r 	 0.215  0.053 (HA/LAMP1)). HA did not show co-local-
ization with Cav1 or cholera toxin subunit B (data not shown).
To confirm that the negative HABP and LAMP1 staining was
not due to rapid HA degradation within lysosomes, cells were
treated with EIPA (a known inhibitor of the Na
/H
 ex-
changer-1 known to activate hyaluronidase 2) before co-stain-
ing with HABP and LAMP1. The results demonstrated a slight
but insignificant increase in co-localization betweenHABP and
LAMP1 in EIPA- and BMP7-treated cells (Pearson’s correla-
tion coefficient mean r	 0.155 0.074 for BMP7-treated cells
versus mean r 	 0.386  0.170 for BMP7- and EIPA-treated
cells) (Fig. 6C).
Enzymatic degradation of HA is initiated by the Hyal group
of enzymes. In somatic tissues, Hyal1 andHyal2 function as the
major hyaluronidases for HA degradation. Hyal1 is found pre-
dominantly intracellularly, and Hyal2 can be found both intra-
cellularly and at the cell surface (36). To determinewhetherHA
internalization by BMP7 stimulationmay be associated with its
breakdown, immunocytochemistry was used to co-stain intra-
cellular HA (i.e. after hyaluronidase treatment of intact cells)
with Hyal1 and Hyal2. Both Hyal1 and Hyal2 demonstrated
some co-localization with intracellular HA. However, the dis-
tribution of HA-Hyal1 and HA-Hyal2 endosomes within the
cells varied. HA-Hyal1 endosomes were distributed in the peri-
nuclear region (Fig. 7A), whereas the HA-Hyal2 endosomes
were located at the nuclear margin (Fig. 7B). Subsequent stain-
FIGURE 6. Internalized HA is distributed into intracellular endosomes. Fibroblasts were grown to 70% confluence before undergoing growth arrest
in serum-free medium for 48 h. Cells were then incubated in serum-free medium alone or serum-free medium containing 400 ng/ml BMP7 and were
subsequently fixed and stained for HABP (green)/EEA1 (red) (A), HABP (green)/LAMP1 (red) (B). Areas of co-localization appear as yellow, original
magnification400. C,HABP (green)/LAMP1 (these cells having been additionally incubated with EIPA). Co-localization scatter plots were performed to
confirm co-localization (depicted as yellow areas), and Pearson’s correlation was used to confirm statistical significance. All images are representative of
three individual experiments.
FIGURE 7. Internalized HA is distributed into intracellular endosomes
containing Hyal1 and Hyal2. Fibroblasts were grown to 70% confluence
before undergoing growth arrest in serum-free medium for 48 h. Cells were
then incubated in serum-free medium alone or serum-free medium contain-
ing 400 ng/ml BMP7 and were subsequently fixed and stained for HABP
(green)/Hyal1 (red) (A) and HABP (green)/Hyal2 (red) (B). Areas of co-localiza-
tion appear as yellow, original magnification400.
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ing forHyal1 andHyal2with EEA1 and LAMP1was performed.
The results indicated that both endosomes and lysosomes con-
tained Hyal1 and Hyal2, with endosomes containing relatively
more Hyal2 than Hyal1 and lysosomes containing more Hyal1
thanHyal2 (Pearson’s correlation coefficient mean r	 0.447
0.048 Hyal1/EEA1, mean r	 0.625 0.220 Hyal2/EEA1, mean
r	 0.748 0.146 Hyal1/LAMP1, and mean r	 0.131 0.052
Hyal2/LAMP1) (Fig. 8, A and B).
BMP7 Drives Marked Alterations in CD44 Distribution and
CD44 Variant Isoform Expression in Fibroblasts—CD44 is the
principal cell-surface HA receptor. This trans-membrane gly-
coprotein can exist asmultiple isoforms due to variable splicing
of exons and exhibits considerable protein diversity (37). Fur-
thermore, its coupling and association with other proteins and
its distribution within the cell membrane are markedly influ-
enced by distinct growth factors (12, 28, 38). Our previouswork
has outlined the importance of TGF-1-driven CD44 redistri-
bution and CD44/EGFR coupling within the cell membrane in
mediating fibroblast to myofibroblast differentiation (12, 27).
Although TGF-1 attenuated total CD44 mRNA expression,
BMP7 increasedCD44mRNA (Fig. 5D).We subsequently used
immunocytochemistry to assess the influence of BMP7 on pro-
tein expression and distribution of CD44 in relation to HA. In
keeping with our previous published research, CD44 was dis-
tributed in distinct areas mainly at the cell surface in resting
fibroblasts (Fig. 9A). In TGF-1-inducedmyofibroblasts, CD44
had lower levels of expression and was distributed diffusely at
the cell surface. Increased pericellular HA was prominent in
these cells (Fig. 9B). BMP7 stimulation alone, or in conjunction
with TGF-1 according to our prevention/reversal experimen-
tal models, led to cell surface as well as intracellular staining of
CD44 (Fig. 9, C–F). CD44 appeared to be localized within dis-
tinct areas both at the cell membrane and in the cytoplasm in
these cells. However, CD44 did not co-localize with HA within
themajority of intracellular vesicles. Co-staining for CD44with
EGFR demonstrated dissociation between CD44 and EGFR in
fibroblasts co-treated with BMP7 and TGF-1, depicted as
reduced yellow staining compared with cells treated with
TGF-1 alone (Fig. 10A). However, co-staining for CD44 and
Hyal2 demonstrated association between these proteins partic-
ularly at the cell surface and the nuclear margin in response to
BMP7 (Fig. 10B, arrows). No similar relationship could be iden-
tified between CD44 and Hyal1 (data not shown).
CD44v7/8 Is Key in Mediating BMP7-driven Prevention and
Reversal ofMyofibroblast Phenotype—The type ofCD44 variant
isoform expressed can relate to different and sometimes oppos-
ing cellular functions (39–41). The influence of TGF-1 and
BMP7 on CD44 variant isoforms in our cell systems was there-
fore investigated. Primers for CD44 variant isoforms were
designed to amplify CD44 exon targets between specific prim-
ers. These primer pairs and conventional RT-PCR expression
of individualCD44 isoformswere used to assess the response to
TGF-1 and BMP7 (data not shown). CD44v7/8 was shown to
have prominent expression in BMP7-treated cells. The PCR
products were subsequently excised and sequenced to confirm
expression. Specific primers were designed for QPCR amplifi-
cation with results demonstrating down-regulation of all vari-
ant isoform expression with TGF-1 (data not shown). In com-
parison, significant up-regulation of variant isoform CD44v7/8
was demonstrated with BMP7, although significant down-reg-
ulation was observed with TGF-1, indicating a possible role
for this isoform in BMP7 prevention of TGF-1 myofibroblast
differentiation (Fig. 11A). CD44v7/8 had moderate level expres-
sion in control fibroblasts, with threshold cycles of amplification
ranging between 28 and 32 out of 40. The threshold cycle varied
between 27 and 29 for BMP7 treatments and was higher (thresh-
oldcycles32–35) and thereforedemonstrated low level expression
in fibroblasts stimulated with TGF-1.
siRNAs targeting CD44v7/8 were used to determine the role
of this variant isoform in the BMP7-mediated changes in HA
internalization and inhibition of myofibroblast phenotypes.
Successful knockdown of CD44v7/8 expression following
siRNA treatment compared with scrambled controls was ini-
tially confirmed (white bars compared with black bars, Fig.
11B). To confirm specificity of the siRNA for this variant of
CD44, CD44v7/8 siRNA transfected fibroblasts were evaluated
for expression ofCD44s and totalCD44. NeitherCD44s expres-
sion (Fig. 11C) nor total CD44 expression (data not shown)
demonstrated significant changes in expression following
transfection with CD44v7/8 siRNA compared with scrambled
controls. The influence of knocking downCD44v7/8 on-SMA
FIGURE 8. Distribution of Hyal1 and Hyal2 in endosomes and lysosomes
in fibroblasts. Fibroblasts were grown to 70% confluence before undergo-
inggrowth arrest in serum-freemedium for 48h. Cellswere then incubated in
serum-freemediumaloneor serum-freemediumcontaining400ng/mlBMP7
andwere subsequently fixed and stained for EEA1 (green) and Hyal1 or Hyal2
(red) (A) and LAMP1 (green) and Hyal1 or Hyal2 (red) (B). Areas of co-localiza-
tion appear as yellow, original magnification 400. Co-localization scatter
plots were performed to confirm co-localization (depicted as yellow areas),
and Pearson’s correlation was used to confirm statistical significance.
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mRNAexpressionwas subsequently assessed (Fig. 11D). Signif-
icant increases in -SMA mRNA expression were observed in
BMP7-treated cells incubated with the CD44v7/8 siRNA com-
pared with scrambled siRNA, although no difference was
observed in theTGF-1-treated cells. This suggests that knock-
down of this variant isoform decreased the ability of BMP7 to
prevent and reverse the TGF-1-mediated myofibroblast phe-
notype. Immunostaining of cells for -SMA also confirmed
maintenance of the myofibroblast phenotype despite BMP7
treatment, with more prominent -SMA staining present in
cells that were incubated with the siRNA targeting CD44v7/8
(Fig. 11F). Moreover, knockdown of CD44v7/8 also inhibited
BMP7-mediated HA internalization into intracellular endo-
somes, with CD44v7/8 siRNA-treated cells showing minimal
HA internalization (Fig. 11E).
Cell-surfaceHyal2 and theNHE1AreAlso Essential forMedi-
ating BMP7-driven Prevention and Reversal of Myofibroblast
Phenotype—Todetermine the role of the hyaluronidases (Hyal1
and Hyal2) in mediating the BMP7-driven changes in preven-
tion and reversal of myofibroblast phenotypes, siRNAs target-
ing Hyal1 and Hyal2 were used to knock down expression of
these proteins. Initial experiments to determine knockdown
were initially performed (Fig. 12, A and B). The effect of inhib-
iting Hyal1 and Hyal2 on -SMAmRNA expression in myofi-
FIGURE 9. BMP7 redistributes HA and CD44 inmyofibroblasts. Fibroblasts were grown to 70% confluence before undergoing growth arrest in serum-free
medium for 48 h. Cells were then incubated under the various cytokine treatments according to the experimental models described under “Experimental
Procedures.” Cellswere subsequently fixed and stained forHABP (green) andCD44 (red). Areas of co-localization appear as yellow, originalmagnification400.
All images are representative of three individual experiments.
FIGURE 10. BMP7 redistributes CD44, EGFR, and Hyal2 inmyofibroblasts. Fibroblasts were grown to 70% confluence before undergoing growth arrest in
serum-free medium for 48 h. Cells were then incubated under the various cytokine treatments according to the experimental models described under
“Experimental Procedures.” Cells were subsequently fixed and stained for EGFR (green) and CD44 (red) (A) and Hyal2 (green) and CD44 (red) (B). Areas of
co-localization appear as yellow, original magnification400. All images are representative of three individual experiments.
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broblasts was then assessed. Knockdown of Hyal1 siRNA did
not influence -SMA expression in our experimental systems
(Fig. 12C). In contrast, Fig. 12D showed thatHyal2 siRNAeffec-
tively inhibited BMP7-dependent attenuation of -SMA
mRNA expression in all treatments. This indicated that knock-
down ofHyal2 inhibited the ability of BMP7 to prevent/reverse
TGF-1-induced myofibroblast phenotype. Immunocyto-
chemical staining for -SMA protein following treatment with
Hyal1 andHyal2 siRNA demonstrated similar results, with the
presence of increased stress fiber formation and -SMA stain-
ing following knockdownofHyal2 but not knockdownofHyal1
(Fig. 12F). HA staining also demonstrated that inhibitingHyal2
but not Hyal1 attenuated BMP7-mediated HA internalization
into cytosolic endosomes (Fig. 12E).
Hyal2 possesses an acidic pH optimum (pH 3.7). Hyal2 has
previously been demonstrated to be present in the cytoplasm
contained within lysosomes (42). However it is also present at
the cell surface linked to the plasma membrane via a glycosyl-
phosphatidylinositol anchor (43). Hyal2 at the cell surface is
activated to its pH optimum through the creation of an acidic
microenvironment by NHE1 (44). NHE1 and Hyal2 have also
been shown to form a complex with CD44s to promote breast
tumor cell invasiveness (44). EIPA is a known inhibitor of
NHE1. To determine the role of cell-surface Hyal2 versus intra-
cellular Hyal2 in BMP7-mediated prevention/reversal of TGF-
1-induced myofibroblast phenotype, NHE1 action was
blocked with EIPA to inhibit cell-surface Hyal2 activity. Myo-
fibroblasts exposed to this treatment did not demonstrate pre-
vention and reversal of phenotype by BMP7 as assessed by
-SMA mRNA expression (Fig. 13A). They also demonstrated
increased -SMA by immunocytochemistry (Fig. 13B) and
reduced HA internalization in response to BMP7 (Fig. 13C).
Furthermore, NHE1 inhibition also appeared to lead to re-as-
sociation betweenCD44 and EGFRmembrane proteins despite
co-treatment of the cells with BMP7 and TGF-1 (Fig. 14). We
also investigated a link between variant CD44v7/8 and Hyal2
(Fig. 15). Dual staining for CD44v7/8 (Fig. 15, green) and
Hyal2 (red) was performed. The results showed that fibro-
blasts demonstrated constitutive protein expression of
CD44v7/8 at the cell surface under basal conditions. Hyal2
and CD44v7/8 did not co-localize under basal conditions
(Fig. 15A). In TGF-1-induced myofibroblasts, CD44v/8
(green) staining was attenuated in line with its reduced
mRNA expression (Fig. 15B). In BMP7-treated cells (Fig. 15,
FIGURE 11. BMP7 drives changes in variant CD44 gene expression, which are essential for mediating BMP7-driven alterations in myofibroblast
phenotype. A, fibroblasts were grown to confluence before growth arrest in serum-freemedium for 48 h. Cells were then treated under various cytokine
conditions, as indicated, before extraction with TRIzol reagent. RNAs were purified, reverse-transcribed, and assessed for CD44v7/8 mRNA expression
using RT-QPCR. B–D, cells were grown to subconfluence and transfected with specific siRNA nucleotides targeting CD44v7/8 for 24 h prior to the
indicated cellular treatments. Cells were then treated under various cytokine conditions according to experimental models as described under “Exper-
imental Procedures” before extraction with TRIzol reagent. RT-QPCR was used to assess CD44v7/8 (B), CD44s (C), and -SMA (D) mRNA expression.
Results are shown as the mean  S.E. of three individual experiments. Statistical significance used the paired Student’s t test, and p  0.05 was
considered as significant. E and F, cells were grown to subconfluence and transfected with specific siRNA nucleotides targeting CD44v7/8 24 h prior to
the indicated cellular treatments. Cells were subsequently fixed and stained for HABP (E) and -SMA (F) as shown. Original magnification400. Images
shown are representative of three individual experiments.
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C–F), CD44v7/8 demonstrated significantly increased
expression at the cell surface; however, no evidence of asso-
ciation was found betweenHyal2 and CD44v7/8 under any of
the BMP7 treatment conditions.
DISCUSSION
Aberrant expression of the cytokine TGF-1 has beenwidely
implicated in progressive fibrosis (45–47). Alongside its direct
effects on extracellular matrix turnover, TGF-1 is the princi-
pal factor known to drive myofibroblast formation, and it is the
persistence of these contractile cells within tissues that predicts
progression of fibrotic disease (48–53). Our previous work has
shown that HA is a major contributor to TGF-1-driven fibro-
sis. TGF-1 promotes HAS2-driven HA generation alongside
increased transcription and translation of the HA-binding pro-
tein tumor necrosis factor-stimulating gene-6 (TSG-6) (12, 33).
TSG-6 binds and stabilizes the newly generated HA matrix
forming TSG-6-dependent HA pericellular coats around indi-
vidual myofibroblasts (54). These HA coats are essential for
driving CD44 redistribution into lipid raft-rich areas within the
cell membrane where it interacts with the EGF receptor, which
triggers a cascade of downstream intracellular signaling events
essential for fibroblast to myofibroblast differentiation (27).
Thus, the HA pericellular coat is essential in maintaining myo-
fibroblast phenotype and in promoting the pro-fibrotic actions
of TGF-1. Alternative forms of HA matrix have also been
identified in fibroblasts and have distinct functions. Our group
has previously shown that the formation of a spiculated HA
pericellular matrix associated with IL-1 stimulation was not
associated with myofibroblast formation. Instead, it led to
enhanced CD44 expression and its co-localization with the
adhesion molecule ICAM-1 resulting in fibroblast-monocyte
binding (28). Thus, the ability of the HA matrix to regulate
cellular functions is well recognized. Therefore, insight into
how BMP7 may orchestrate an anti-fibrotic HA matrix that
antagonizes the pro-fibrotic TGF-1-driven matrix becomes
imperative for understanding the mechanisms through which
BMP7 can prevent and reverse fibrosis. However, in this work
we demonstrate that BMP7-driven prevention and reversal of
TGF-1-mediatedmyofibroblast formation was not associated
with a distinct pericellular HAmatrix. Rather, BMP7 promoted
internalization of HA and loss of the TGF-1-driven HA peri-
cellular matrix. HA was internalized into intracellular catalytic
endosomes containing Hyal1 and Hyal2. Furthermore, inter-
nalization of HA through this pathway was dependent on dis-
FIGURE 12. BMP7-driven alterations in myofibroblast phenotype are Hyal2-dependent. Cells were grown to subconfluence and transfected with
specific siRNA nucleotides targeting Hyal1 (A and C) and Hyal2 (B and D) for 24 h prior to the indicated cellular treatments according to experimental
models before extraction with TRIzol reagent. RT-QPCRwas used to assess Hyal1 (A), Hyal2 (B), and -SMA (C andD) mRNA expression. Results are shown
as the mean S.E. of three individual experiments. Statistical significance used the paired Student’s t test, and p 0.05 was considered as significant.
E and F, cells were grown to subconfluence before transfection with specific siRNA nucleotides targeting Hyal1 or Hyal2 for 24 h prior to the indicated
cellular treatments. Cells were subsequently fixed and stained for-SMA (E) and HABP (f). Original magnification400 Images shown are representative
of three individual experiments.
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sociation between CD44 and EGFR (55), and it was also depen-
dent on cell-surfaceHyal2 and recruitment of the CD44 variant
isoform, CD44v7/8.
The principal HA receptor, CD44, is widely expressed in
mammalian tissues andhas been shown to have important roles
in inflammation, tumor progression, embryogenesis, and
FIGURE 13. Blockade of NHE1with EIPA inhibits BMP7-driven prevention and reversal of myofibroblast phenotype. A, cells were grown to confluence,
growth-arrested, and then treated under various cytokine conditions as indicated, before extraction with TRIzol reagent. RNAs were purified, reverse-tran-
scribed, andassessed for-SMAmRNAexpressionusingRT-QPCR. Results are shownas themean S.E. of three individual experiments. Statistical significance
was assessed using the paired Student’s t test, and p 0.05 was considered as significant. B and C, fibroblasts were grown to 70% confluence before growth
arrest in serum-free medium for 48 h. Cells were then incubated under the various cytokine treatments, as indicated, and subsequently fixed and stained for
-SMA (B) and HABP (C). Original magnification400, and all images are representative of three individual experiments.
FIGURE 14. Blocking NHE1 with EIPA prevents BMP7-driven EGFR/CD44 disassociation. Fibroblasts were grown to 70% confluence before growth arrest
in serum-free medium for 48 h. Cells were then incubated under the various cytokine treatments according to experimental models as described under
“Experimental Procedures.” Cells were subsequently fixed and stained for EGFR (green) and CD44 (red). Areas of co-localization appear as yellow, original
magnification400. All images are representative of three individual experiments.
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immune cell activation as well as fibrosis (16, 37, 56–58). This
cell adhesion molecule can function as a co-receptor as well as
bind growth factors and other (non-HA) components of the
extracellular matrix (37). It contains a short cytoplasmic tail
withmultiple phosphorylation sites, a transmembrane domain,
and an extracellular domain that contains an amino-terminal
HA binding domain containing a link module (55, 59, 60).
Alternative splicing of exons encoding the extracellular domain
leads to formation of variant CD44 isoforms (CD44v) and is the
basis for structural and functional diversity of this protein.
Standard CD44 (CD44s) is the most abundantly expressed and
simplest of all CD44 variants, containing only the common
extracellular amino-terminal domain, transmembrane domain,
and cytoplasmic region. All other variants have this overall pat-
tern but include additional amino acids in the stem structure to
produce different sized molecules. Other researchers, particu-
larly in the cancer field, have demonstrated that the CD44 var-
iant isoforms can have distinct modes of action and divergent
functions (61–64). In the field of renal disease, the overexpres-
sion of the variant isoformCD44v3 has been shown to limit the
actions of TGF-1 and confer renoprotective properties in
mice in a model of unilateral ureteric obstruction (39). In pul-
monary fibrosis, variant isoforms CD44v6 and CD44v9 have
shown reduced expression compared with normal lung tissues
(65). Other than these two studies, the potential role of variant
CD44 isoforms in the promotion and/or prevention of fibrotic
disease has received little attention. In our previous work, we
have demonstrated the importance of the pericellular HA
matrix in dictating overall CD44 membrane interactions and
membrane distribution (54). In this study we have shown that
TGF-1 and BMP7 differentially regulate overall CD44 expres-
sion. Although TGF-1 attenuates CD44 expression, BMP7
augments CD44 expression, in particular significantly increas-
ing expression of the variant isoform CD44v7/8. This CD44
variant is translated frommRNAcontaining exons 11 and 12, in
addition to the standard exons encodingCD44s (exons 1–5 and
15–19). Inhibiting this CD44 variant blocks BMP7-mediated
HA internalization as well as inhibiting the actions of BMP7 in
prevention and reversal of the TGF-1-induced myofibroblast
phenotype. Thus, it is clear that CD44v7/8 is essential in medi-
ating the beneficial actions of BMP7 in human fibroblasts.
The mechanisms through which this occurs are not yet
clearly identified and will be the subject of future study. How-
ever, a number of potential mechanisms may be involved. Pre-
vious research has shown that in addition to its role as a signal-
ing receptor, CD44 also has an important role in internalization
of HA for degradation (66). Hence, this variant isoform may
specialize inHA internalization rather than themaintenance of
a TSG-6-HA-CD44-dependent pericellular coat. Likewise,
other studies have shown that the affinity of the HA-CD44
bond can vary, and the strength of the HA-CD44 interaction
can influence the resulting CD44-driven cellular responses (42,
67–69). CD44v7/8 may exhibit either enhanced or dampened
affinity for HA, which promotes dissolution of the HA coat and
interferes with TGF-1-dependent signal transduction. Alter-
natively, in preference to interaction with the EGF receptor,
CD44v7/8 may interact with other, as yet unidentified, mem-
brane components that facilitate BMP7-driven responses.
Thus, studies of the CD44 variant isoform (particularly
CD44v7/8) mechanism of alternative splicing, modes of action,
and distinct functions are potentially a promising field in fibro-
sis research.
The data presented in this study also denote the importance
of Hyal2 in mediating the actions of BMP7. Hyal2 is an acid
active enzyme generally found in two forms. It has been
reported to exist in the cytoplasm within lysosomes (42). It has
also been found anchored to the cell surface via a glycosylphos-
phatidylinositol link (43). Cell-surface Hyal2 is thought to have
FIGURE 15.CD44v7/8 andHyal2donot associate at the cell surface. Fibroblastswere grown to 70%confluence before growth arrest in serum-freemedium
for 48 h. Cells were then incubated under the various cytokine treatments according to experimental models as described under “Experimental Procedures.”
Cells were subsequently fixed and stained for Hyal2 (red) and CD44v7/8 (green). Areas of co-localization appear as yellow, original magnification 400. All
images are representative of three individual experiments.
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weaker enzymatic activity, but it has been reported to have a
number of nonenzymatic functions, including forming com-
plexes with other membrane proteins and regulation of Smad-
driven promoters (70). The bulk of HA cleavage by cell-surface
Hyal2 is thought to occur in acidic pockets generated byNHE1,
which catalyzes the extrusion of intracellular H
 in exchange
for extracellular Na
 (44). In our experiments, blocking NHE1
activity and inhibiting Hyal2 had the same effects, which led us
to propose that cell-surfaceHyal2 and not intracellular Hyal2 is
central to mediating BMP7 actions. Activated Hyal2 catalyzes
high molecular mass HA into intermediate size fragments of
20 kDa (50 disaccharides). Thus, Hyal2 in our system may
also be contributing to dissolution of the HA coat with subse-
quent CD44v7/8-mediated internalization of the HA frag-
ments. In breast cancer cells, cell-surfaceHyal2 has been shown
to form a functional complex with CD44 andNHE1. This led us
to assume that a similar process may be occurring in our cell
systems utilizing the variant isoform CD44v7/8 along with
NHE1 and Hyal2. However, no co-localization was apparent
between this variant isoform and Hyal2 in our experiments. In
other work, overexpression of Hyal2 led to CD44 shedding
from lipid rafts (71). Thus, the functional link between
CD44v7/8 and Hyal2 in promoting BMP7 actions in our cell
system is not yet understood.However, we have also shown that
NHE1 and cell-surface Hyal2 play significant roles inmaintain-
ing dissociation of the CD44-EGFR complex by BMP7. We
know from our previous work that the CD44-EGFR complex
promoted by TGF-1 resides within lipid rafts at the cell mem-
brane. Therefore, Hyal2 (activated by NHE1) may be necessary
to shed CD44 from lipid raft membrane fractions following
BMP7 stimulation, resulting in its dissociation from EGFR.
HA internalized as a consequence of BMP7 action was found
contained within intracellular endosomes. The HA-containing
endosomes also positively stained for Hyal1 and to a greater
extent, Hyal2. The HA-Hyal1- and HA-Hyal2-containing
endosomes appeared to occupy distinct areas within the cyto-
plasm, with the HA-Hyal1 endosomes being contained within
the perinuclear region and the HA-Hyal2 endosomes being
located at the nuclear margin. These findings led us to propose
that HA internalized by BMP7 was targeted for degradation.
The different cytoplasmic localization of HA-Hyal1- and
HA-Hyal2-containing endosomes supports a stepwise process
of HA degradation similar to that reported by previous investi-
gators (72, 73). It was surprising that internalized HA did not
associate significantly with lysosomes. It is possible that the
little association betweenHAandLAMP1 could be due to rapid
HA degradation within lysosomes, thus rendering the HA
undetectable. Inhibition of Hyal2 activity using EIPA did not
significantly increase the association between HA and LAMP1.
However, EIPA does not inhibit Hyal1 activity, and it may not
markedly influence Hyal2 activity in already acidic lysosomes.
Thus, these experiments do not preclude the internalization of
HA into lysosomes as well as endosomes for degradation.
The observation of intracellular HA in this study adds to a
growing number of recent studies demonstrating intracellular
HA in various states of synthesis or degradation. Increasingly,
data in this field suggest that intracellular HA may also be
involved in regulating cellular function. HA within cells has
been localized to diverse locations, including nuclei, nucleoli,
cytoskeleton, and endoplasmic reticulum, and it has been
implicated in processes such as cell motility, cell cycle control,
RNA splicing, and regulation of the mitotic spindle (74–83).
Furthermore, the presence of intracellular hyaladherins (such
as CD44 and RHAMM) and the indication that HA may be
synthesized intracellularly raise the question as to whether
intracellular HA and its associates can serve as-yet undefined
functions (84). In mesangial and other cells, intracellular accu-
mulation of HA has been associated with a high glucose envi-
ronment and has been linked to the process of cell autophagy
(85). In our cell systems, we showed that although BMP7 drove
increased CD44v7/8 expression at the cell surface, leading to
internalization of otherCD44molecules into the cytoplasmand
subsequent co-localization with HA-Hyal2 vesicles at the
nuclear margin. The functional consequences of these changes
are unclear from this study, However, it has been shown in
previous research that the intracellular domain of CD44 can
undergo cleavage and translocate to the nucleus resulting in
altered gene transcription (86). Hence the study of intracellular
HA and its associates may be another important avenue to pur-
sue in understanding the anti-fibrotic actions of BMP7.
In summary, this study has shown that BMP7 antagonizes the
pro-fibrotic effects of TGF-1 in fibroblasts and myofibroblasts
through dissolution and internalization of the TSG-6 and CD44-
EGFR-dependent pericellular HA coat into hyaluronidase-con-
taining endosomes. These events are dependent on increased
expression of CD44v7/8 at the cell surface, along with the com-
bined actions of cell-surfaceHyal2 andNHE1, thus identifying key
mediators of BMP7 action important for future study.
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